Teva Innovative Medicine & Biosimilar Pipeline
By development stage – as of November 2025
- Novel Biologics
- Small Molecules
- Biosimilars
Approved
Under Regulatory Review
Biosimilar to Xgeva®
(denosumab)Biosimilar to Prolia®
(denosumab)Clinical
Phase 3
More information
Phase 3 clinical trials are larger trials typically conducted with up to several thousand participants and are designed to establish if the intervention is safe and effective in preparation for product approval. The results show whether or not the intervention is beneficial to a particular group of participants.
Phase 2
More information
Phase 2 clinical trials are conducted with up to several hundred participants. They are designed to collect additional information about whether the intervention is safe and effective. The results of these types of clinical trials may be used to design future trials or to develop additional research methods.
Phase 1
More information
Phase 1 clinical trials are small-scale clinical trials with very few participants to examine the way the intervention (e.g., medication) interacts with the human body. The purpose of the study is to collect information about the safety of the interventions assessed. These trials are typically conducted in healthy participants without a specific medical condition.
Pre-clinical
More information
More information about this phase in drug development.
Teva innovative medicine and biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.
Pipeline is current as of November, 2025